SEC Form 4 · accession 0000899243-17-014458
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffery Kutok
Officer — Chief Scientific Officer
Period of report
May 25, 2017
Accepted (ET)
May 26, 2017 · 8:21 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.74 | May 25, 2017 | A | 125,000 | A | — | May 25, 2027 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1The option vests over a period of two years in equal annual installments on the first and second anniversary of the date of grant.